J. Marcsisin

Safety and efficacy of apremilast through 104 weeks in patients with moderate to severe psoriasis who continued on apremilast or switched from etanercept treatment: findings from the LIBERATE study

R. Petric, M. Gooderham, A. Bewley, 2017, Journal of the European Academy of Dermatology and Venereology : JEADV.